GO:0070164 negative regulation of adiponectin secretion: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0070164 describes any process that stops, prevents, or reduces the regulated release of adiponectin from a cell, as defined by QuickGO.
• Adiponectin secretion is controlled at both transcriptional and post-translational levels, including by the co-repressor RIP140 and by ER-to-Golgi trafficking pathways.
• Reduced adiponectin secretion is linked to obesity, insulin resistance, and cardiometabolic disease, making this GO term clinically relevant.
• RIP140 is a well-characterized negative regulator of adiponectin secretion; its knockdown increases adiponectin release.
• Studying GO:0070164 requires models that distinguish secretion from total adiponectin production, such as knockout and knock-in cell lines.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect negative regulation of adiponectin secretion.
Description
Adiponectin is an adipokine with insulin-sensitizing, anti-inflammatory, and cardioprotective properties, and its circulating levels are inversely associated with obesity and metabolic syndrome. The amount of adiponectin released from adipocytes is not determined solely by its synthesis; it is also controlled by negative regulatory processes that reduce its secretion. GO:0070164, negative regulation of adiponectin secretion, captures these inhibitory mechanisms. Understanding this term is essential because impaired adiponectin secretion contributes to the pathophysiology of obesity-related disorders, including insulin resistance and cardiovascular disease. At the molecular level, adiponectin secretion is regulated transcriptionally and post-translationally, with factors such as receptor interacting protein 140 (RIP140) acting as a negative regulator. Post-translational control includes ER-to-Golgi trafficking and multimerization, which are required for efficient secretion. This article integrates QuickGO annotation with published literature to provide a research-grade overview of GO:0070164, its mechanisms, key genes, disease relevance, and experimental strategies for investigation.
negative regulation of adiponectin secretion At A Glance
| GO ID | GO:0070164 |
|---|---|
| GO term | negative regulation of adiponectin secretion |
| Ontology | biological_process |
| Synonym | down regulation of adiponectin secretion, down-regulation of adiponectin secretion, downregulation of adiponectin secretion, inhibition of adiponectin secretion |
| Major function | Inhibits the regulated release of adiponectin from cells, primarily adipocytes. |
| Related cellular component | Secretory vesicles, endoplasmic reticulum, Golgi apparatus |
| Related molecular function | Transcriptional corepressor activity, protein binding |
| Regulatory examples | RIP140 (NRIP1) represses adiponectin secretion |
| Disease relevance | Obesity, insulin resistance, type 2 diabetes, cardiovascular disease |
What Is GO:0070164?
According to QuickGO, GO:0070164 (negative regulation of adiponectin secretion) is defined as any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of adiponectin from a cell. This biological process encompasses molecular events that inhibit the secretory pathway of adiponectin, including transcriptional repression, post-translational modifications, and interference with vesicular trafficking. It is distinct from positive regulation of adiponectin secretion and from general regulation of adiponectin production.
Why Is negative regulation of adiponectin secretion Important in Cell Biology?
Negative regulation of adiponectin secretion is critically important because adiponectin is a key hormone that enhances insulin sensitivity and protects against inflammation and atherosclerosis. When its secretion is excessively suppressed, circulating adiponectin levels drop, contributing to the development of obesity-linked metabolic complications such as insulin resistance, type 2 diabetes, and cardiovascular disease. Therefore, understanding the mechanisms that negatively regulate adiponectin secretion can reveal therapeutic targets to restore adiponectin levels and improve metabolic health.
• Adiponectin is an insulin-sensitizing adipokine; its reduced secretion is a hallmark of obesity and type 2 diabetes.
• Negative regulation of adiponectin secretion contributes to the low adiponectin levels observed in obese individuals.
• RIP140 (NRIP1) is a transcriptional corepressor that inhibits adiponectin secretion; its dysregulation may link to metabolic disorders.
• Impaired adiponectin secretion is associated with cardiovascular disease and endothelial dysfunction.
• Adiponectin secretion is regulated post-translationally, including through ER-Golgi trafficking, which can be targeted by negative regulators.
• Understanding this process may inform strategies to increase adiponectin levels in metabolic diseases.
• Adiponectin resistance in obesity may involve both reduced secretion and reduced sensitivity.
• Animal studies suggest adiponectin also influences appetite regulation, though its role is controversial.
• Marrow fat-secreted factors, including adiponectin, may serve as biomarkers for osteoporosis.
• Studying negative regulation of adiponectin secretion can uncover novel therapeutic targets for metabolic syndrome.
What Happens During negative regulation of adiponectin secretion?
Transcriptional repression of adiponectin
In simple terms: Certain proteins can block the gene that makes adiponectin, reducing how much is produced and secreted.
Adiponectin secretion is partly controlled at the transcriptional level. The co-repressor RIP140 (receptor interacting protein 140) negatively regulates adiponectin secretion by repressing the adiponectin gene promoter. Knockdown of RIP140 increases adiponectin secretion, demonstrating its inhibitory role. This transcriptional control is a key mechanism within GO:0070164.
Post-translational regulation of adiponectin secretion
In simple terms: After the protein is made, its journey out of the cell can be slowed or blocked.
Adiponectin secretion is also regulated post-translationally. The protein undergoes multimerization and trafficking through the endoplasmic reticulum (ER) and Golgi apparatus, and disruptions in these steps reduce secretion. Negative regulators can interfere with these processes, thereby decreasing the amount of adiponectin released.
ER-to-Golgi trafficking and secretory vesicle transport
In simple terms: Adiponectin must travel through the cell's export machinery; blocking this route reduces secretion.
Efficient secretion of adiponectin requires its proper folding and assembly into multimers in the ER, followed by transport to the Golgi and packaging into secretory vesicles. Negative regulation of adiponectin secretion can occur by impairing any of these steps, leading to intracellular retention and reduced release.
Regulation by hormonal and metabolic signals
In simple terms: Hormones and metabolic conditions can send signals that tell fat cells to hold back adiponectin.
Hormonal and metabolic signals influence adiponectin secretion. For example, in obesity, elevated levels of certain factors may suppress adiponectin release. Additionally, FGF21 has been shown to protect against heart failure with preserved ejection fraction by improving cardiac mitochondrial bioenergetics, but its direct role in adiponectin secretion regulation is not established. The interplay of such signals contributes to the negative regulation of adiponectin secretion.
Key Genes Involved in GO:0070164 negative regulation of adiponectin secretion
The following genes and proteins have been implicated in the regulation of adiponectin secretion, with a focus on negative regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ADIPOQ | Encodes adiponectin, the substrate of this process | Central to all studies of adiponectin secretion |
| NRIP1 (RIP140) | Transcriptional corepressor that negatively regulates adiponectin secretion | Knockdown increases adiponectin secretion |
| PPARG | Nuclear receptor that promotes adiponectin expression | Positive regulator, indirectly opposes negative regulation |
| FOXO1 | Transcription factor that can repress adiponectin expression | Potential negative regulator |
| SIRT1 | Deacetylase that modulates adiponectin secretion | May influence negative regulation |
| ERp44 | ER protein involved in adiponectin multimerization and secretion | Post-translational regulation |
| Ero1-Lalpha | Oxidoreductase that facilitates adiponectin assembly | Post-translational regulation |
| GGA1 | Golgi-localized protein involved in trafficking | Potential negative regulator of secretion |
| VPS4 | ESCRT component affecting vesicular trafficking | Potential regulator of secretion |
| RAB5 | Small GTPase involved in endosomal trafficking | May influence adiponectin secretion |
| RAB11 | Regulates recycling endosomes | Potential role in secretion |
| ARF6 | Regulates vesicular trafficking | Potential negative regulator |
| PLIN1 | Lipid droplet protein, affects adipocyte function | Indirect regulator of adiponectin secretion |
| FGF21 | Metabolic hormone with cardioprotective effects | Not directly linked to adiponectin secretion |
| LEP | Leptin, another adipokine | May interact with adiponectin regulation |
| INS | Insulin, key metabolic hormone | Regulates adiponectin secretion indirectly |
| TNF | Pro-inflammatory cytokine that reduces adiponectin | Negative regulator of adiponectin secretion |
| IL6 | Inflammatory cytokine linked to reduced adiponectin | Negative regulator |
How Is negative regulation of adiponectin secretion Regulated?
The negative regulation of adiponectin secretion is controlled by multiple mechanisms. Transcriptional repression by RIP140 (NRIP1) directly inhibits adiponectin gene expression. Post-translational regulation includes ER-to-Golgi trafficking and multimerization, which can be disrupted by various factors. Hormonal signals such as insulin, TNF-alpha, and IL-6 can suppress adiponectin secretion in obesity. Additionally, FGF21 has been shown to improve cardiac function but its direct effect on adiponectin secretion is not well defined. These layers of regulation ensure that adiponectin release is tightly controlled according to metabolic needs.
negative regulation of adiponectin secretion and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NRIP1 (RIP140) | Obesity, insulin resistance | Knockout or knockdown in adipocytes |
| ADIPOQ | Type 2 diabetes, cardiovascular disease | Overexpression or knock-in in adipocytes |
| TNF | Insulin resistance, inflammation | Knockout in adipocytes or macrophages |
| IL6 | Obesity-related inflammation | Knockout in adipocytes |
| FGF21 | Heart failure with preserved ejection fraction | Knockout or overexpression in mice |
Obesity and Insulin Resistance
Obesity is characterized by low circulating adiponectin levels, which contribute to insulin resistance and type 2 diabetes. Negative regulation of adiponectin secretion is enhanced in obesity, partly due to increased inflammatory cytokines such as TNF-alpha and IL-6. RIP140, a negative regulator, may also play a role in this context. Restoring adiponectin secretion is a potential therapeutic strategy.
Cardiovascular Disease
Adiponectin has protective effects on the cardiovascular system, and reduced adiponectin secretion is associated with increased cardiovascular risk. Negative regulation of adiponectin secretion may exacerbate endothelial dysfunction and atherosclerosis. FGF21, which protects against heart failure with preserved ejection fraction, may indirectly influence adiponectin, but direct evidence is lacking.
Obstructive Sleep Apnea
Obese patients with severe obstructive sleep apnea have altered levels of adiponectin and other adipokines. Negative regulation of adiponectin secretion may contribute to the metabolic disturbances observed in these patients.
Osteoporosis
Marrow fat-secreted factors, including adiponectin, have been proposed as biomarkers for osteoporosis. Negative regulation of adiponectin secretion could affect bone metabolism, though the exact mechanisms require further study.
From negative regulation of adiponectin secretion-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate adiponectin secretion? | CRISPR knockout of gene X in adipocytes, measure adiponectin secretion |
| Does a specific point mutation in gene X affect its function? | CRISPR point mutation knock-in in adipocytes |
| Does overexpression of gene X reduce adiponectin secretion? | CRISPR knock-in of a strong promoter or cDNA overexpression |
| Does tagging gene X affect its localization? | CRISPR knock-in of a fluorescent tag |
| Does gene X regulate adiponectin secretion in vivo? | Knockout mouse model |
| Can a drug restore adiponectin secretion? | Pharmacological screening in adipocyte cell lines |
How to Study the negative regulation of adiponectin secretion Process
| Method | What It Measures | Typical Application |
|---|---|---|
| ELISA | Adiponectin concentration in media | Quantify secretion from adipocytes |
| Western blot | Adiponectin protein levels in cells and media | Assess secretion and intracellular retention |
| qRT-PCR | Adiponectin mRNA levels | Determine transcriptional regulation |
| Luciferase reporter assay | Promoter activity | Test transcriptional repression by RIP140 |
| Co-immunoprecipitation | Protein-protein interactions | Identify regulators of adiponectin trafficking |
| Fluorescence microscopy | Subcellular localization of adiponectin | Visualize secretory pathway |
| CRISPR screening | Genes affecting adiponectin secretion | Unbiased discovery of negative regulators |
| Proteomics | Global protein changes | Identify pathways involved in secretion |
Measuring Adiponectin Secretion
Adiponectin secretion is typically measured by ELISA or Western blot of conditioned media from adipocytes. This distinguishes secreted from intracellular adiponectin, allowing assessment of negative regulation.
Transcriptional Analysis
Quantitative RT-PCR and promoter-reporter assays can determine if a negative regulator acts at the transcriptional level. For example, RIP140 represses the adiponectin promoter.
Proteomic and Interactomic Approaches
Mass spectrometry-based proteomics can identify proteins that interact with adiponectin or its trafficking machinery, revealing potential negative regulators.
Imaging of Secretory Pathway
Fluorescence microscopy of tagged adiponectin can visualize its trafficking through the ER and Golgi, helping to pinpoint where negative regulation occurs.
How CRISPR Can Be Used to Study GO:0070164 negative regulation of adiponectin secretion
Knockout
CRISPR knockout of candidate negative regulators (e.g., NRIP1) in adipocytes can confirm their role in suppressing adiponectin secretion. Knockout of RIP140 increases adiponectin secretion, validating its function.
Point Mutation
Introducing point mutations in genes such as NRIP1 can dissect functional domains required for repression of adiponectin secretion. This helps identify critical residues for interaction with the adiponectin promoter.
Knock-in
Knock-in of a fluorescent tag or a promoter reporter into the ADIPOQ locus allows real-time tracking of adiponectin secretion and regulation. This can be used to screen for negative regulators.
Overexpression
Overexpression of suspected negative regulators via CRISPR knock-in of a strong promoter or cDNA can test whether increased levels reduce adiponectin secretion. This is useful for validating gain-of-function effects.
How EDITGENE Supports negative regulation of adiponectin secretion Research
Researchers studying negative regulation of adiponectin secretion-related genes often need to determine whether a candidate gene is causally involved in suppressing adiponectin release. This requires precise genetic manipulation to avoid confounding effects from compensatory pathways. EDITGENE provides a comprehensive suite of CRISPR services to enable such studies.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of adiponectin secretion research.
Frequently Asked Questions About negative regulation of adiponectin secretion
What is GO:0070164?
GO:0070164 is the Gene Ontology term for negative regulation of adiponectin secretion, defined as any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of adiponectin from a cell.
What genes are involved in negative regulation of adiponectin secretion?
Key genes include NRIP1 (RIP140), which encodes a transcriptional corepressor that inhibits adiponectin secretion. Other factors such as TNF and IL-6 also negatively regulate adiponectin secretion.
How is adiponectin secretion negatively regulated?
It can be regulated at transcriptional levels by corepressors like RIP140, and post-translationally by interfering with ER-to-Golgi trafficking and multimerization.
Why is negative regulation of adiponectin secretion important?
Because reduced adiponectin secretion contributes to obesity-related metabolic diseases such as insulin resistance, type 2 diabetes, and cardiovascular disease.
What diseases are associated with reduced adiponectin secretion?
Obesity, insulin resistance, type 2 diabetes, cardiovascular disease, and obstructive sleep apnea have been linked to low adiponectin levels.
How can I study negative regulation of adiponectin secretion?
You can use CRISPR knockout, knock-in, overexpression models, and measure secreted adiponectin by ELISA or Western blot.
What is the role of RIP140 in adiponectin secretion?
RIP140 is a transcriptional corepressor that negatively regulates adiponectin secretion; its knockdown increases secretion.
Can CRISPR be used to study adiponectin secretion?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect the regulatory mechanisms.
What are the research methods for adiponectin secretion?
Common methods include ELISA, Western blot, qRT-PCR, luciferase assays, and imaging of fluorescently tagged adiponectin.
How does obesity affect adiponectin secretion?
Obesity is associated with decreased adiponectin secretion, partly due to increased negative regulators like TNF-alpha and IL-6.
Conclusion
GO:0070164, negative regulation of adiponectin secretion, is a critical biological process that controls the release of the insulin-sensitizing adipokine adiponectin. Dysregulation of this process contributes to obesity, insulin resistance, and cardiovascular disease. Key regulators such as RIP140 have been identified, and post-translational mechanisms including ER-Golgi trafficking play important roles. Using CRISPR-based models, researchers can dissect these pathways and identify new therapeutic targets. EDITGENE provides comprehensive services to support such studies.
References
- 1. Zhang K et al.. 2025. FGF21 protects against HFpEF by improving cardiac mitochondrial bioenergetics in mice.. Nat Commun 16(1):1661 PMID: 39955281
- 2. Ho PC et al.. 2012. Negative regulation of adiponectin secretion by receptor interacting protein 140 (RIP140).. Cell Signal 24(1):71-6 PMID: 21872658
- 4. Engin A. 2017. Adiponectin-Resistance in Obesity.. Adv Exp Med Biol 960:415-441 PMID: 28585210
- 5. Zhang DM et al.. 2018. Adiponectin, Omentin, Ghrelin, and Visfatin Levels in Obese Patients with Severe Obstructive Sleep Apnea.. Biomed Res Int 2018:3410135 PMID: 30151379
- 6. Tang N et al.. 2021. The Controversial Role of Adiponectin in Appetite Regulation of Animals.. Nutrients 13(10) PMID: 34684387
- 7. Herrmann M. 2019. Marrow Fat-Secreted Factors as Biomarkers for Osteoporosis.. Curr Osteoporos Rep 17(6):429-437 PMID: 31734905
- 8. Liu M et al.. 2009. Transcriptional and post-translational regulation of adiponectin.. Biochem J 425(1):41-52 PMID: 20001961
